Why Ativan Must Be Diluted for IV Administration
Ativan (lorazepam) must be diluted with an equal volume of compatible solution before intravenous injection to prevent vein irritation, ensure proper mixing, avoid air entrapment, and allow for controlled administration at the required slow injection rate of no more than 2 mg per minute. 1
FDA-Mandated Dilution Requirements
The FDA drug label is explicit and unequivocal: "PRIOR TO INTRAVENOUS USE, ATIVAN INJECTION MUST BE DILUTED WITH AN EQUAL AMOUNT OF COMPATIBLE DILUENT" 1. This is not a suggestion—it's a mandatory requirement for safe IV administration.
Specific Dilution Instructions
When preparing for IV use 1:
- Mix with equal volume of Sterile Water for Injection, Normal Saline, or 5% Dextrose
- Gently invert repeatedly until homogenous—do NOT shake vigorously as this causes air entrapment
- Inject slowly at maximum 2 mg/minute into vein or existing IV tubing
- Inspect visually for particulates or discoloration before administration
Clinical Rationale for Dilution
1. Vein Protection
Undiluted lorazepam causes significant venous irritation. Historical data shows that while undiluted diazepam caused pain in 87% of patients and thrombophlebitis in 6-16%, lorazepam has "minimal irritative or injurious effects on veins whether undiluted or diluted" 2. However, dilution further minimizes even this low risk, particularly in small hand or arm veins 3.
2. Controlled Titration
Dilution enables the slow injection rate mandated by the FDA. Rapid IV push of concentrated lorazepam increases risk of:
- Respiratory depression
- Hypotension
- Loss of airway reflexes
- Excessive sedation 1
The 2002 ASA guidelines emphasize that "intravenous sedative/analgesic drugs should be given in small, incremental doses that are titrated to the desired end points" with "sufficient time between doses to allow the effect of each dose to be assessed" 4.
3. Prevention of Intra-arterial Injection
The FDA label warns: "CARE SHOULD BE TAKEN TO DETERMINE THAT ANY INJECTION WILL NOT BE INTRA-ARTERIAL AND THAT PERIVASCULAR EXTRAVASATION WILL NOT TAKE PLACE" 1. Dilution with slow administration allows immediate recognition if the patient complains of pain—stop immediately if pain occurs during injection as this may indicate arterial placement or extravasation.
Critical Safety Context
Respiratory Monitoring Requirements
When administering IV lorazepam 1:
- Start IV infusion and monitor vital signs
- Maintain unobstructed airway
- Have artificial ventilation equipment immediately available
- Airway obstruction may occur even at therapeutic doses, particularly when combined with other CNS depressants
Special Populations
The dilution requirement applies universally, but be especially cautious in:
- Patients >50 years: More profound and prolonged sedation 1
- Hepatic/renal disease: Use with caution; avoid in hepatic/renal failure 1
- Hemodynamically unstable patients: Avoid loading doses 5
Common Pitfall to Avoid
Do NOT use undiluted lorazepam IV even though it can be given undiluted IM. The label on the vial states "For Intramuscular use. For Intravenous use, dilution required" 1. The routes have different requirements—IM can be given undiluted deep in muscle mass, but IV absolutely requires dilution.
The 2013 Critical Care guidelines note that lorazepam has a 15-20 minute onset after IV loading dose 5, which is slower than midazolam (2-5 minutes). This delayed onset makes proper dilution and slow administration even more critical to avoid stacking doses before the full effect is apparent.